MedCity News December 5, 2025
Freenome’s SPAC merger agreement comes as the liquid biopsy developer prepares for potential 2026 commercialization of SimpleScreen, a colorectal cancer test currently under FDA review. If approved, the Freenome blood test would compete against Guardant Health’s liquid biopsy, Shield.
Freenome, developer of tests that identify early signs of cancer from a small sample of patient blood, is going public in a merger deal that will infuse the company with $330 million to support a pipeline that could yield its first commercialized test in 2026.
The early cancer detection company is merging with Perceptive Capital Solutions Corp, a special purpose acquisition company (SPAC) sponsored by an affiliate of Perceptive Advisors, the firms announced Friday. The combined company will take the Freenome...
Today's Sponsors
Today's Sponsor